We came across a bullish thesis on Omnicell, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on OMCL. Omnicell, Inc.'s share was trading at $38.61 as of February 18th. OMCL’s trailing P/E was 912.50 according to Yahoo Finance. Why Impact Biomedical Inc. (IBO) Surged On Thursday? Elena Pavlovich/Shutterstock.com Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies th ...

Core Thesis - Omnicell, Inc. is positioned for transformative growth by shifting from hardware-driven revenue to a software- and services-led model, with a current share price of $38.61 and a trailing P/E of 912.50 [1][2] Group 1: Revenue and Growth Strategy - The company is currently generating approximately $1.18 billion in revenue and aims to double sales to around $2.4 billion by 2031, primarily through high-margin SaaS offerings and Expert Services [3] - Strategic acquisitions, such as ANiGENT in October 2025, are expanding Omnicell's footprint in drug diversion detection, enhancing recurring revenue streams [3] Group 2: Market Position and Competitive Advantage - Long-term growth is anticipated from the vision of an "Autonomous Pharmacy," where AI and robotics manage all medication handling, addressing healthcare labor shortages expected by 2030 [4] - Omnicell's competitive advantage includes high switching costs, over 900 patents, and a large installed base that supports proprietary AI capabilities, although competition from companies like Becton Dickinson necessitates ongoing innovation [4] Group 3: Financial Outlook and Valuation - As recurring revenue approaches nearly 50% of total revenue, margins are projected to expand from the low teens to the mid-20s, supported by strategic acquisitions and debt reduction [5] - The bull case suggests a potential fivefold increase in valuation if Annual Recurring Revenue (ARR) exceeds $1.5 billion, with a market re-rating from a traditional medical equipment multiple to a Healthcare IT multiple [6]

We recently published 10 Stocks Ending February With a Bang. Dentsply Sirona Inc. (NASDAQ:XRAY) was one of the best performers on Friday. Dentsply bounced back by 15.50 percent on Friday to finish at $14.68 apiece, as investor sentiment was boosted by announcements of a share repurchase program, which overshadowed the termination of its quarterly dividends. In an earnings call on Thursday, Dentsply Sirona Inc. (NASDAQ:XRAY) said that it initiated a new capital allocation as part of its corporate restruc ...

26 February 2026 | 7:33AM CST Equity Research United Imaging (688271.SS): FY25 prelim results beat with strong 4Q25 performance; Buy United Imaging released its FY25 preliminary results on Feb 25, 2026. Both its revenue (Rmb13,821mn, +34% yoy) and net profit (Rmb1,888mn, +50% yoy) beat GSe (Rmb12,574mn/1,616mn). This prelim results implied a +48% yoy revenue growth in 4Q25, and we anticipate +44%/+61% yoy growth for the company's China domestic and overseas businesses in 4Q25, which translate to +30%/+49% y ...

Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance [Accessibility Statement] Skip Navigation- Introduces full-year 2026 organic sales growth, adjusted EPS and free cash flow guidance- Reported sales decreased 3.7%; organic sales increased 3.5%ST. PAUL, Minn., Feb. 26, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the fourth quarter and year ended December 31, 2025.Fourth Quarter 2025 Highlights- Operating cash flow of $96 million ...

Xtant Medical to Participate in the Canaccord Genuity 2026 Musculoskeletal Conference [Accessibility Statement] Skip NavigationBELGRADE, Mont., Feb. 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, today announced that Sean Browne, CEO, Scott Neils, CFO, and Mark Schallenberger, COO, will be participating in the Canaccord Genuity 2026 Musculoskeleta ...

[https://mma.prnewswire.com/media/2855663/Polaroid_Theraphuetics_Logo.jpg]SOURCE Polaroid Therapeutics## 21%[more press release views with Request a Demo]## Also from this source### Polaroid Therapeutics (PTx) recibe la marca CE para POLTX_Fiberâ"¢[Polaroid Therapeutics (PTx) anuncia hoy que POLTX_Fiberâ"¢ ha recibido la marca CE como dispositivo médico de Clase IIb con APTâ"¢ (TecnologÃa de...]### Polaroid Therapeutics (PTx) erhält das CE-Zeichen für POLTX-Fiber™: die erste Anwendung von APT™ zur Einführun ...

Key Takeaways HSIC beat Q4 earnings and revenue estimates as sales rose 7.8% year over year. HSIC saw strong growth in equipment, specialty products and cloud-based tech adoption. Margins narrowed as gross margin fell 19 bps and adjusted operating margin slipped 57 bps. Henry Schein, Inc. (HSIC) registered fourth-quarter 2025 adjusted earnings per share (EPS) of $1.34, up 12.6% from the year-ago period’s figure. The bottom line also surpassed the Zacks Consensus Estimate by 3.1%.Excluding adjustments, such ...

Novanta (NasdaqGS:NOVT) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Company ParticipantsMatthijs Glastra - Chair and CEORay Nash - Corporate Finance LeaderRobert Buckley - CFOConference Call ParticipantsBrian Drab - Equity Research AnalystLee Jagoda - Equity Research AnalystRob Mason - Managing Director and Senior Research AnalystOperatorAlso note, today's event is being recorded. At this time, I'd like to turn the conference call over to Ray Nash, Corporate Finance Leader for Novanta. Please go ahe ...

Stryker launches Synchfixâ"¢ EVT, expanding options for flexible syndesmotic fixation [Accessibility Statement] Skip NavigationElevating care with Stryker's next generation device, [Synchfix EVT], which will be featured at the 2026 American College of Foot and Ankle Surgeons (ACFAS) Annual MeetingPORTAGE, Mich., Feb. 24, 2026 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced the launch of Synchfixâ"¢ EVT, its next-generation flexible syndesmotic fixation device designed ...